ANIP — ANI Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $1.37bn
- $1.46bn
- $486.82m
- 97
- 38
- 94
- 90
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 207 | 208 | 216 | 316 | 487 |
Cost of Revenue | |||||
Gross Profit | 143 | 121 | 116 | 178 | 305 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 190 | 224 | 256 | 352 | 440 |
Operating Profit | 16.4 | -16 | -39.8 | -35.3 | 47 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 3.16 | -26 | -56.1 | -62.7 | 19.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | 6.09 | -22.5 | -42.6 | -47.9 | 18.8 |
Net Income Before Extraordinary Items | |||||
Net Income | 6.09 | -22.5 | -42.6 | -47.9 | 18.8 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 6 | -22.5 | -42.8 | -49.5 | 15.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.864 | -1.25 | -2.78 | -2.81 | 0.91 |